Zhijun Guo

Mr. Zhijun Guo is the Chief Technology Officer at Immorna and Co-founder of the Immorna family of companies. He has more than 30 years of scientific and leadership experience in the infectious disease vaccine industry.

Prior to co-founding Immorna with Dr. Zihao Wang, Mr. Guo was Associate General Manager at King-Cell Biotechnology (Shanghai) where he established the full quality system to support the drug whole lifecycle management and led the GMP compliance taskforce. Prior to King-cell, Mr. Guo worked for more than 15 years at Tianyuan Biopharmaceutical Co. Ltd. (part of Novartis Vaccine Diagnostics, then GSK Vaccines) with increasing technical and leadership roles. He was Head of the Manufacturing Science & Technology function before he left GSK Vaccines. Mr. Guo is a well-recognized expert in CMC development, tech transfer, process validation, and GMP manufacturing. He also has extensive experience in regulatory submission for all phases of vaccine clinical trials and commercial product registration. He led the successful registration of GSK and/or Novartis’ Rabies Vaccine, Quadrivalent Influenza Vaccine, and HPV Vaccine.

Mr. Guo holds an MBA degree from the University of Montpellier in France.